ME/CFS Treatment Insurance Denied: How to Appeal
ME/CFS treatment denied by insurance? CDC and NIH recognize ME/CFS as a serious disease. Learn how to document and appeal denials for this misunderstood condition.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multi-system disease that severely impairs the lives of an estimated 836,000 to 2.5 million Americans. Despite formal recognition by the CDC, NIH, and WHO, and despite the NIH's RECOVER and ME/CFS research initiatives investing hundreds of millions of dollars, insurance coverage for ME/CFS treatment is routinely and often incorrectly denied. Here is what you need to know.
What Is ME/CFS?
ME/CFS is a serious, chronic, complex disease characterized by:
- Profound fatigue that is not improved by rest and has lasted at least 6 months
- Post-exertional malaise (PEM): A hallmark feature—worsening of symptoms after even minimal physical or cognitive activity, lasting hours to days
- Unrefreshing sleep: Sleep that does not restore energy
- Cognitive impairment: Memory problems, difficulty concentrating, "brain fog"
- Orthostatic intolerance: Worsening symptoms when upright (often POTS-like)
Diagnosis is clinical, based on the 2015 National Academy of Medicine (NAM/IOM) criteria, which require all three core symptoms (fatigue, PEM, unrefreshing sleep) plus at least one of cognitive impairment or orthostatic intolerance, for at least 6 months and significantly reducing activity from pre-illness baseline.
ME/CFS has ICD-10 codes: G93.32 (ME/CFS, post-COVID) and G93.3 (Post-viral fatigue syndrome), with G93.39 established for non-COVID ME/CFS.
Why ME/CFS Treatment Is Denied
"No Objective Findings" Defense
The most common denial argument: ME/CFS lacks the kind of objective markers—a positive blood test, visible lesion on imaging—that insurers use to validate medical necessity. This argument contradicts the scientific literature: ME/CFS has documented abnormalities in immune function, mitochondrial energy metabolism, autonomic nervous system regulation, and microbiome composition. The absence of a single diagnostic test is not the same as the absence of biological disease.
"Psychiatric/Psychosomatic" Misclassification
A legacy of historical misclassification has led to some physicians and insurers treating ME/CFS as primarily a psychiatric or psychosomatic condition. This misclassification has been officially repudiated by the CDC, NIH, and the 2015 NAM report, which describe ME/CFS as "a serious, chronic, complex systemic disease that often can profoundly affect the lives of patients."
Graded Exercise Therapy (GET) Now Discouraged—But Still Prescribed
For decades, GET (gradually increasing physical activity) and Cognitive Behavioral Therapy (CBT) aimed at activity increase were the recommended treatments based on now-challenged research. The PACE trial, which underpinned these recommendations, has been extensively criticized for methodological flaws. Both the CDC and UK NICE guidelines (updated 2021) have explicitly removed GET from recommended ME/CFS treatment, noting it can worsen PEM. Insurers who require GET completion before approving other management are applying outdated and harmful protocols.
Symptom Management Denied as "Not ME/CFS Treatment"
Because no FDA-approved disease-modifying treatment exists for ME/CFS, treatment consists of symptom management: medications for pain, sleep, POTS/dysautonomia, and cognitive symptoms. Insurers sometimes deny these as "not specifically treating ME/CFS"—an inappropriate application of coverage criteria to a condition managed through its component symptoms.
Disability Claims Denied
ME/CFS is among the most commonly denied conditions in long-term disability insurance. Insurers argue that functional limitations cannot be objectively confirmed, despite the fact that 2-day CPET (cardiopulmonary exercise testing) demonstrating PEM-induced VO2 max reduction is a validated, objective tool for demonstrating functional impairment.
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
How to Appeal an ME/CFS Treatment Denial
Lead With Formal CDC and NIH Recognition
Your appeal letter should open by establishing ME/CFS as a recognized, serious medical condition: "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is formally recognized by the CDC (cdc.gov/me-cfs), the NIH, and the World Health Organization (ICD-10: G93.3) as a serious, complex disease. The 2015 National Academy of Medicine report characterized ME/CFS as a 'devastating, complex, multisystem disease.'" This directly counters "psychosomatic" or "lifestyle" denial reasoning.
Use the 2015 NAM Diagnostic Criteria
Document explicitly how your patient meets the 2015 Institute of Medicine criteria: at least 6 months of substantially reduced functioning, at least three core symptoms (fatigue, PEM, unrefreshing sleep), and at least one additional symptom (cognitive impairment or orthostatic intolerance). PEM must be documented specifically—this is the pathognomonic feature that distinguishes ME/CFS from general fatigue conditions.
Document PEM Objectively
PEM documentation strengthens any ME/CFS appeal. Options include:
- 2-day CPET testing showing reduction in VO2 max and work rate on Day 2 vs. Day 1 (the gold standard for demonstrating PEM)
- Cognitive testing scores before and after an activity challenge
- Symptom diaries documenting exacerbation patterns following activity
- Wearable activity tracker data showing step count collapse after active days
Challenge Outdated GET Recommendations
If the insurer is requiring GET completion, cite NICE guidelines directly: "The NICE ME/CFS guideline (2021) explicitly states that graded exercise therapy (GET) should not be offered to people with ME/CFS, as programmes based on the premise that ME/CFS is perpetuated by deconditioning can worsen symptoms and cause harm." The CDC has similarly removed GET from its recommendations.
Document Symptom Treatment as Medically Necessary
For each medication or therapy being denied, frame it as treating a specific, documented condition: "Low-dose naltrexone is prescribed for documented inflammatory pain and cognitive dysfunction in the context of ME/CFS. Beta-blockers are prescribed for documented orthostatic intolerance (POTS) confirmed by tilt table testing." Connecting each treatment to an objective, documented symptom is more defensible than arguing for "ME/CFS treatment" generally.
For Disability Denials: Submit 2-Day CPET Results
Two-day CPET is the most powerful tool for disability appeals because it provides objective data showing that the patient's functional capacity is further impaired the day after exertion—the physiological signature of PEM. This is the most defensible evidence against an insurer's "no objective findings" argument. Work with an ME/CFS specialist or exercise physiologist experienced in 2-day CPET interpretation.
File a Complaint With the State Insurance Commissioner
ME/CFS denials that misclassify the disease as psychiatric or that apply outdated treatment criteria may violate mental health parity laws or state-specific insurance regulations. Filing a parallel complaint while appealing applies regulatory pressure that often accelerates resolution.
Fight Back With ClaimBack
ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.
Fight your denial at ClaimBack →
Related Reading:
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides